Objective: Guidelines recommend informed decision-making regarding prostate specific antigen (PSA) screening for men with at least 10 years of remaining life expectancy (RLE). Comorbidity measures have been used to judge RLE in previous studies, but assessments based on other common RLE measures are unknown. We assessed whether screening rates varied based on four clinically relevant RLE measures, including comorbidities, in a nationally-representative, community-based sample.
Introduction
Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is prevalent, 1-4 despite on-going uncertainty about the mortality benefits of PSA screening and consequent concern over the negative impacts from testing. 5, 6 Disappointingly, recently-published, long-anticipated randomized controlled trials of PSA screening did not resolve this uncertainty. [7] [8] [9] [10] the potential benefits of early treatment, risking overscreening. 11 However, with the increasing proportion of healthy older men expected to live more than 10 years, 12 excluding all men from PSA screenings could result in at-risk, otherwise healthy men not receiving screening. 13 Deciding which men to screen should therefore rely on more than age alone. As a response to the uncertain benefits of screening, PCa screening recommendations have been based on estimated remaining life expectancy (RLE) rather than age, and they emphasize informed, shared decision-making. Two physicians' groups, the American Cancer Society (ACS) and the American Urological Association (AUA), recommend that men with a RLE of at least 10 years have an opportunity to make an informed decision about whether to be screened for PCa. 14, 15 In contrast, preliminary U.S. Preventive Services Task Force (USPSTF) guidelines recommend against PSA-based screening for PCa. 7, 16 Despite the differences, all guidelines recommend against screening for those with limited RLE. Unfortunately, little guidance has been given to physicians on systematic approaches to estimating RLE, and currently, little is known about how RLE estimations are applied to actual clinical practice. Prior studies examining the relationship of RLE to PSA screening rates did not include several potential measures known to estimate RLE in community-dwelling, older adults. 11, 13, [17] [18] [19] [20] Previous studies have instead mainly used comorbidities as their measure of RLE. 11 Given this, we use a recent, nationally-representative sample of communitydwelling older adults in the United States to assess four well-known and clinically-relevant measures of RLE, including comorbidities, self-rated health, functional status, and a performance assessment. We examine whether the relationship of RLE to PSA screening varies based on which RLE measure is used, as well as the relationship of a combined RLE measure to PSA screening.
Methods

Study Design
Using data from the National Social Life, Health, and Aging Project (NSHAP), a nationally-representative survey of 3005 community-dwelling individuals aged 57-85 in the United States. 21 Data collection took place from July, 2005 through March, 2006, with a response rate of 75.5%. In-person interviews were conducted by trained professionals. 22 A full account of sampling procedures, instrument development, and interview procedures for NSHAP are published elsewhere. 21, 22 All men over 65 years old are included for analysis. After excluding 89 individuals for missing information on primary variables and 129 individuals with a prior history of PCa, the final sample size was 709 men.
PSA Screening
The primary outcome measure is the self-reported use of a screening PSA test. [1] [2] [3] 23 
RLE Measures
Men were grouped into RLE categories of 0-7 years, 8-12 years, and 13+ years. These categories were chosen based on a 10-year RLE cut-off found in most guidelines, 19, 24 then conservatively allowing for a two-year RLE "window" on either side of 10. 25 Four specific measures to estimate RLE were assessed: a comorbidity index, self-rated health, physical performance, and functional health. A Charlson comorbidity index was chosen because it is well-validated, relatively simple to use, and provides objective information on clinically significant conditions from a questionnaire form. 26, 27 Self-rated health, which has been consistently shown to be a predictor of RLE, was measured using the question, "Would you say your health is excellent, very good, good, fair, or poor?" 28 Functional status
was assessed by asking if the individual can walk one block, and by the ability to perform activities of daily living (ADL). 29 Finally, the timed up and go (TUG) test, a common clinical tool that is associated with mortality, [30] [31] [32] was also used as a performance assessment to place individuals into RLE categories. The TUG test was performed only on an NSHAP subsample (n = 327).
Estimating RLE
We used two literature-supported approaches for RLE estimates: one based on life table calculations and the other on national RLE data ( Table 1) . Life tables were used for the selfrated health and functional status measures. Questionnaire responses were stratified by the age of the respondent, and 
Combined Measure of RLE
In addition to evaluating the relationship of individual RLE measures to PSA screening, the relationship of a combined measure utilizing all four RLE measures to PSA screening was assessed. There are inherent limitations in the accuracy of individual RLE estimations; therefore the purpose of this additional analysis was to understand rates of screening in men for whom informed decision making would be very unlikely to be useful (i.e. when all measures indicate RLE of 0-7 years) or when there is a possibility of benefit requiring further conversation (all measures indicate RLE of 13+ years). Men were grouped into categories of 0-7 years RLE if all measures indicated 0-7 years of RLE, or 13+ years RLE if all measures indicated 13+ years of RLE. For simplicity, all other men were grouped into the category "discordant RLE estimation." Because TUG was administered only to a subsample of NSHAP, a combined analysis was done separately for men with available TUG data (4 RLE measures) and men for whom TUG data was unavailable (3 RLE measures).
Covariates
Several factors other than RLE known to be related to PSA screening were included as covariates. Age was stratified into 5 year age groups for descriptive statistics, and used as a continuous variable in regressions. Ethnicity, marital status, and socioeconomic status, including education and income, have all been associated with PSA screening. 2, 3, 11, 23, [37] [38] [39] [40] Ethnicity was self-reported. Marital status was defined as currently married or unmarried. Education was divided into four categories: "less than high school," "high school diploma/ GED," "some college/vocational degree," and "bachelors or more." Income was defined based on percentage of the federal poverty level (FPL) for single adult and 2 adult households, 41, 42 with the categories "poor" (0-100% FPL), "near-poor" (101-200% FPL), "not poor" (>200% FPL), and "unknown" if they did not respond. Health care access was assessed by using the number of visits to a doctor's office in the last 12 months. Individuals with certain health-related behaviors, such as low alcohol use, low smoking rates, and regular exercise, have higher rates of PSA screening.
2 Therefore, three dichotomous health behavior variables were included: tobacco use, alcohol consumption, and exercise. 43, 44 These variables were included as covariates due to the likelihood of patient preferences for "prevention" influencing the screening process. Tobacco use was based on whether the individual smokes 
Statistical Analysis
First, descriptive statistics were calculated to characterize the distributions and rates of PSA screening for each variable (Tables 3 and 4) . 21 Multivariable logistic regression models were used to test the independent relationship of RLE based on each measure to rates of PSA utilization (Table 5) . Estimated rates of PSA screening in the last year for each logistic regression model were calculated (Fig. 1) . In the combined analysis, we conducted bivariate analysis to illustrate the degree of concordance and discordance between different RLE estimations (Table 6 ). Finally, the adjusted PSA screening rates for the combined measures of RLE were calculated (Fig. 2) . All statistical analyses were performed using NSHAP sample weights in Stata 11.0 (StataCorp, College Station, TX). The study was approved by the Institutional Review Board at the University of Chicago. Individuals with better self-rated health had more PSA screenings in the last year, with 54.1% in the "excellent health" group receiving a screening, compared to 34.5% in the "poor health" group. This was similar for the TUG test results. In contrast, men with higher co-morbidity scores received more screenings in the last year compared to individuals with low co-morbidity scores.
Logistic Regression Results (Table 5)
In the self-rated health RLE regressions, the adjusted model indicated that individuals in the 13+ RLE group have a significantly higher odds of receiving a PSA test than individuals in the 0-7 RLE group (OR = 6.82, p < 0.001). For functional health RLE and the TUG test RLE, there was a similar, but weaker, trend for PSA utilization in comparison to self-rated health. In contrast, for the co-morbidity index RLE, there was no significant RLErelated trend with the 13+ year RLE category having an OR of 1.50 (p = 0.09). Visits to the doctor were strongly predictive of PSA screening in the adjusted logistic regression model for all RLE estimates (results not shown). The relationship of RLE to PSA screening significantly strengthened when controlling visits to the doctor for both comorbidities (OR = 43.6; p < 0.001) and self-rated health (OR=45.7, p < 0.001). In the fully-adjusted model, self-rated health RLE was most closely associated with PSA test use, where estimated rates of PSA test use were 29.9% for 0-7 years, 50.6% for 8-12 years, and 67.9% for 13+ years ( Fig. 1) . Co-morbidity RLE had the least association with PSA test use for estimated rates.
Combined RLE Analysis
Bivariate comparisons of each RLE variable show the concordance/discordance between each RLE estimation measure (Table 6 ). In the comparison of self-rated health and comorbidity index RLE, 8.3% of men were placed in 0-7 years RLE for both estimations, 35.1% were placed in 13+ years RLE for both estimations, and 48.2% had discordant estimations. Interestingly, 9.0% of men were placed in the 0-7 years RLE category by the comorbidity index, but placed in 13+ years RLE by self-rated health. The self-rated health and functional health RLE estimations were most concordant, in which 85.7% of men were placed in the same category. Overall, 5.2% of men with four RLE measures and 7.1% of men with only three RLE measures available were placed in 0-7 years RLE by all measures. Men who were estimated to have 0-7 years RLE by all four measurements combined had an adjusted PSA screening rate of 43.3%, and men with 13+ years RLE by all measurements had an adjusted screening rate of 65.6% (Fig. 2) . Those with discordant RLE estimates were inbetween.
Discussion
Consistent with guideline recommendations at the time of the NSHAP wave 1 survey (2005), RLE does modestly correlate with PSA screening rates, with some variation in correlation based on which RLE measure is used. However, our results provide additional evidence of high rates of inappropriate PSA screening regardless of how RLE is calculated. 11 For men estimated to have a limited RLE by all four measures, after controlling for other related factors, over a third of individuals with an RLE estimated to be less than 7 years were screened in the last year. We believe this is the first article to compare the relationship of several clinically-appropriate RLE measures to PSA screening in a representative population.
Why there are high rates of apparently inappropriate PSA screening is unknown, but our results support two possibilities. First, the regression analysis suggests increasing exposure to the health care system is related to over-screening, since controlling for visits to the doctor significantly strengthened the relationship of RLE with guideline-recommended PSA screening for each RLE measure. This trend is consistent with data showing that geographic areas with more "technologically aggressive" care have more PSA utilization. 45 Another consideration is the dynamic of patient-physician discussions regarding screening. Physicians are more likely to initiate discussions about PSA tests than patients (including with older patients and those with more comorbidities), and these discussions can take place without a careful consideration of both the harms and benefits of the PSA test. 46, 47 Consequently, physician-initiated discussions, combined with poor communication regarding the overall utility of PSA screening tests, may lead to men who are very unlikely to receive benefit being tested. 46, 48 Other explanations for increased screening may include a response to patient preferences or a consequence of sicker patients being more accepting of additional tests.
11
A second explanation may be that certain measures for estimating RLE, while available for research purposes, 42 are difficult to apply in practice and difficult for practicing physicians to use in estimating RLE. For example, we found that the RLE measurement based on an established comorbidity index was less correlated with guideline-based screening than other measures, such as self-rated health. In bivariate analysis, individuals with more comorbidities had higher rates of PSA testing than those with less, as some others have noted. 11, 13 This is consistent with other studies which have shown that physicians often have a difficult time estimating 10-year RLE based on comorbidities and often report feeling uncertain when applying these RLE estimates to decisions. 49 Additional longitudinal work is necessary to clarify which measures are the best clinical tools for guiding RLE-based screening recommendations. 25 We acknowledge some limitations in our study. First, our study relied on self-reported PSA testing rates, which may be subject to recall bias or other inaccuracies. 50, 51 Nevertheless, our national estimates of PSA test use are comparable to those from other studies. 3, 4, 11 Second, our data is crosssectional, which limits inferences regarding causality. Additional work incorporating a longitudinal component using future waves of the NSHAP data, which is currently being collected, could help address this limitation.
In conclusion, our results improve upon previous work assessing the relationship between clinically-relevant RLE measures and PSA screening. Men consistently estimated to have limited RLE by a variety of methods continue to receive significant amounts of PSA screening. Furthermore, alternative RLE estimators appear to provide different assessments of the relationship of RLE to PSA screening rates. Future Fig. 2 -Adjusted marginal mean PSA screening rates using combined RLE measures. Model is adjusted for age, ethnicity, marital status, education, income, exercise, tobacco, alcohol, and visits to the doctor. Bars indicate a 95% confidence interval. Four measure analysis was performed on a subsample having the TUG information (n = 327), and includes self-rated health, functional health, comorbidities, and TUG/performance status. Three measure analysis was performed on the entire sample (n = 709), and includes self-rated health, functional health, and comorbidities. Abbreviations: RLE-remaining life expectancy, TUG-timed up and go test.
research should focus on identifying the most appropriate RLE estimators in guiding appropriate discussions regarding informed, shared decision-making in cancer screening.
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